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~ 3  Increased Intlmel Hyperplssla In Patients With 
Impaired Glucose Tolerance After Coronary 
Slant Implantation: A Serial intrsvasoutar 
Ultrasound Study 
T, Takngl. K, Yoshida, 1". Ak.sa.ska, 1". Hozuml. S, KeII, 1". Kaw.smoto, Y. Ueds. 
S, Morloka. Kot~ Gon~ml He.spiral, Kobe. Jaf~an 
Intravasculnr ultrasound (IVUS) has shown that exaggerated Intimal hyper. 
pls81a (IH) l= responsible tor the granter I.ste lumen IDeS In slanted lesion In 
dl~betlc patients. To determine whether Impaaired glucose tolerance (IGT) In. 
duoe a greater IH. we studied 28 slanted lesion with Palms~.~ch~lt~ slant in 
R2 pati.snts (pto), Opts had normal glucose tolerance, and 14 pin h~d IGT no. 
cording to cdtodA outllnod by the Wodd Health Organization; fasting plasma 
gklgOSa concentration (FPG) below 14g mg/dl and a plsoms glucose con. 
centrntion (P. hrPO) between 140 nnd 199 mg/dl 2 hour~ after oral glucose 
challenge, ~artat (postinterventten a d follow.up at 6 months) IVU9 wee par, 
formed using ~utom~tlo pullback at 0,5 mm/.s, A cross oectlonol image within 
steal was selected ev.sry 1 mm pullb.sck, and stont area (SA), lumen ares 
(LA), IH ere~ (IHA - SA - LA) W.sre maMured using computer pt~inimstry and 
averaged over number ot 8.sleeted tram.as, 
Reputt,~,' (table), 
Nolm~t IGT 
~pt= (~O ~t~nt#) t4 pt~ (18 ~tent,) 
FPG (m~l) ~ ~; 4 t03 t t~, na 
2~rPG(mgl~l) tt~l 18 le~ '~ le p-0.0001 
HbAI(~ (%) ,58 I 8~ 86 I 07 p ,- 0,0t 
~ma~e in LA (ram 0) ~'O ~ 0,8 ~ A t I 1 p = Q,03 
Increase In IHA (ram 0) 1,0 :t O,S ~? ~ 1,0 p = 002 
~ n :  Sarlsl IVUS analysis howed greater intlm.sl hyperpl,lsta fter 
comn.sry .stont implant.sliDe m patt.snta with IGT, 
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~ U I o  of HMG.CoA Radu©tssa Inhlbltors la 
Associated With Lower Plasma Interleukln-5 
Levels and a Favoursbla Cardiac Course In 
Unstable Angina 
P, Verheggen, M, do Mast, F, Havarkate, V,M, Cats. Dept of Cardiology, 
Leiden Unt~,ersih/ M~,dicaf Center, and Gaub~us Laboratory TNO-PG, LeMen, 
The Netherlands 
Activation oi inflammation reflected by increased intefleuktn-6 ilL-6) levels 
is associated with untavourabla outcome in unstable angina, Treatment with 
plasma lipid Iowedng 3-hydrexy-3-mathylglutaryl-coenzyme A (HMG,CoA) 
reductase Inhlbttors (stattnes) deers.sees cardiac events In coron.sry a,le~ 
disease, possibly by attenu.stiog inflammatory activdy in the vessel wall, In a 
prospective study we determined plasma IL-6 levels in 211 patients admitted 
with unstable angina and comalated the usa of statlnes on admission with lev- 
els ot IL-6 and cltnlcat outcome dunng 18 months follow up, We hypothesized 
that use of stattn,~ isassociated with a favoureble clinical course by modifying 
the Intlammatory process involved, reflected by decreased levels of IU6, In the 
group of patients using a stalin (simvastatlne or pravastatine) (N = 26, group 
A), mean concentration of IL-6 was significantly lower than in the group of 
non-users (t,~ = 185, group B) (geom. mean (cv) 2.36 (0.67) versus 3,46 (0.70) 
ng/L, p = 0.01). Mean tot.el and HDL-cholesterol levels were comparable in 
both groups, In group A, more patients were female and had a cardiac history. 
After adjustment for those factors, the difference according to IU6 levels and 
outcome remained (p = 0,004), During 18 months follow up, no patients in 
group A experienced amajor cardiac event, i,e. acute myocardial infamtion or 
cardiac death, against 29 (16%) in group B, We conclude that patients using a 
stalin while admitted with unstable angina, have significantly lower IL-6 levels 
as comparrd with non-users. Decreased inflammatory activity, reflected by 
lower plasma IL-6 levels, may be a link between use of HMG-CoA reductase 
inhibltors end favourable outcome in coronary artery disease, i,e. unstable 
angina. 
• Effect of Pravsstatln on Thromboganlc- 
Flbrlnolytlc Parameters In Hypemholaaterolemlo 
Patients 
G. Gullets, M,A, Letaee, C~ntro Cardlologla Preventive U,S,S.L, 7 Lecco, 
8ostelo Parinl • LC, Italy 
Oxidized LDL mw Impair .several protective anticoagulant tune!tons, includ- 
ing tl.saue pl.ssmlnogen activator (tPA) and plaemlnooon activator inhibitor 
(PAl-t) balancing, We studied 105 hyporcholeetorelomie paftonte (60 female, 
45 m.sle, aped 56 • 6 yre) 1o assess th~ offo~t ot pmvastaftn 20 ~ daily 
orally admlnlnt.sr~:l on ftbdnogon (FOR), Lg(a), PAid, tPA, PAl.t/tPA ratio (R), 
dimer D (DDM), compared to vnnafton of total chok~taml iTCH), LDL and 
HDL plasma levels, All undenwnt ~l 3 months panod of diab~fy fat m~tfietmn 
end included in the ,study when TCH ~R40 mg/dl was ati!l pm~mt, 
Lp(a), tPA, PAI-t and DDM warn ~sured  usll~l Ells~ In l~st  immu- 
noan]~/mstic method, Measurements were detected on baMI em~tdttmn a d 
altar fat mst~fton (DIET), ¢2 :~ 1.1 months (PRAI) and 10,0 • 1,6 monroe 
(PRAII) of therapy, 
The following results were obtained add compared by means of pa~md 
data t test, 
1~ g^AL DIET PR& l pRA U 
TCH 21~6 t 46 2?8 t SO 228 * 42' 216 t 35' 
LOL t0~ ¢ 43 18~, t: 45 145 z 39' 131 :t 25" 
HDL 53~ t0 54t t5 58*23 60~'  
LlPiCq 39 ~ 32 38 ~i ~ ~9 t 26 30 t 28 
FEIR 33,5 t ?6 ~34 ~ ;~8 336 t 82 ~ t 6? 
DDM 253 ~ 181 ~59 :t t68 2el t too 334 ~. uLs' 
PAI.t ?4 t, ~5 ]'3 t ~ 54 :t 25' 48. ~1" 
tPA 85 • 34 80 * 36 127 ~ 35' 131 ± 3e' 
R e,9~ 31 86 ~ 33 43t  to" 3? :L 17" 
PRAi, PRAIIvSBASAL: ' p.  0,001 * p not 
It'.s concluded that pravastatin reducing TCH and LDL amelmrates the 
thrombegenic-tibnnolytic balance with a shift towa~ 5L~m~'ys:s of PAI-t~IPA 
ratio. Diet had no beneficial affect, 
• Lipid Auessment  and Hypercholesterelemla 
Management: Assessment of Primary Care 
Physician and Cardiologist Practice 
B.M. Mikolich, J.R. Mikolich, I. Onjnchak, R.E. Hunt, G J. Mazanek. 
N,B, Nicoloff, NortheasWm Oh/o Unt~,~Jtms Co//ege o/ 
(NECJCOM), Y'oungs~wn, Oh~ USA 
Methods: One year after the most recent recommendations of the National 
Cholesterol Education Prelect (NCEP) were published, a ratrospectwe study 
of over 1,000 patient charts at a cardDology referral center was conducted. 
Cherts were reviewed for compliance with NCEP recommendatlo~ns. 623 pa- 
tients were identified with a diagnosis which merited assessment of serum 
lil~ids or treatment ol hypedipidemia. 
Results: Serum lipicls were assessed by the pnmary care physician (PCP) 
in 159 of 623 cases (25.5%). The cardiologist assessed lipids in 371 of 464 
patients (80%). Evidence of ask redt_mEon intent by the PCP was found in 87 
of 143 patients (60.8%) with abnormal ipid values, whereas evidence of nsk 
reduction intent was documented in 329 of 368 patmnts (89.4%) identified with 
abnormal ipid values by a cardiologist. Among patients treated for hypedipi- 
demia by a PCP. NCEP goals were met in 6.3% of treated patients. Of those 
patients treated by a cardiologist for hypedipidemia, 26.1% were documented 
to have met NCEP recommendations. 
Conclusion: Serum lipids are more likely to be assessed by a cardiolo- 
gist than by a PCP, among patients with an indication for lipid evaluation. If 
hyperlipidemia is detected, patients are more likely to meet NCEP recom- 
mendations when managed by a cardiologist, in comparison to a PCP. Efforts 
to improve cholesterol screening and treatment among patients with known 
cardiovascular disease require further promulgation among all clinicians, es- 
pecially primary care physicians. 
• Lipid Modifying Therapy for Long-term Survivors 
of Myocardial Infarction 
A. Zambanini C.J. Ellis, ,LK French, I,T, Straznicky, T. Hyde, M. Denton. 
T. Wilson, H.O. White. Green Lane Hospital. Auckland, New Zealand 
Studies from the US and Europe suggest that there is suboptimal lipid man- 
agement in patients with coronary heart disease. We evaluated lipid therapy 
in long-term survivom of myocardial infarction who were enrolled in 3 random- 
ized clinical trials of thrombelytic therapy, and given dietary advice. 
Methods: Between May 1995 and February 1997, at a median of 5.5 years 
after infarction [IQR 4.1-8.9 years], 641 patients had fasting serum lipids 
measured. 
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Resu/~: Lq~l measurements were: total chol~J~tefol (C) 219 ± 38 mg/dl, 
HDL.C 42 ± 11 mg/dl, LDL-C 146 ~: 35 rng/dl, Tnglycerldes 73 ~. 42 m~'dt, 
Lq0~! mo~lymg ll~a~y ~ ~ in 210 pat~e~m (33%) w~th 185 patients 
(29%) taking slatms or flbrat~ alone, Two of morn agents were u ,~ to med+ty 
Nrnmt ~ m 16 patttmlS (2.5%), Utlt¢i~l 1997 AlIA gu~lefines, 447 pat~ent~ 
(7o%) ~ requ~e furm~ ~ mod~r,g t~mpy as LOL.C ¢o~t~r~ 
Of I00 patmnls who had undmgone¢ofonaqf artery by l~ 9 ,~ng (CAOG), 
6~ MdaI~Um LOL.C ~130m0/dl ar~191 ipatle~ts had a sen~n LOI..C ~!00 
m0~+ Slalm o~ Itlwat+ dmm~ we+~ reed m ~ pamml= wm'~ o~e Imt~ race+v- 
melt lwo Imtle~+ 
mm~e ~ ~ mmmmm ,+ mm,~ ~ m mime+ mmmm 
alltml~m ink- 
~ ~ ¢ f  k .m ~n Ik~mm 
M.H, ID, lilS~$o~, K+C, Maki't, H.H ~Itmmcl~t~, J. 0 " ~  . '  ~ C, emer 
k x , ~ ~  ~ ~ U S ~ z ~ ~  Conmmw~ 
B~rgmaz,~" 4HPMC) =s a semm/nlhe~ pelysa¢+ 
c~mde t~'m~ forum ~ ge~ m N 0mmmnemma, w ct. ~ .s  m=mtam 
! o ~  and lemsemalmn, The pu~¢~e t ~ ~ eoul~e-.l~m~ 
p~a~o-¢e,,W~ed study was ~ evsk~e ~e a~r~ of m~ee dine ~ of 
HPl~IC to feclu~ LO~ ct to~l~ m men a~:h,~¢~en with f f~ld-to-modera~ 
rmma~. ~ (Lm. ~ 130--,~0 mgtdL). 
Mea~01s.- N~r at least O weeks on a NabonaJ Cho~kml~ol ~ I~o- 
~ S~S~ I d,e~ tl~O imn=immm ,m~re ramlkm~ a==~r~ed Io ono of lout 
tmaueem arms: ~ 4cell, _,~,~) m ~ a~ doses ol 2.5 9 qd (w~h l~e 
moma~ meal), 2.5 9 I~L o~ 3.75 9 I~I fo+ a 6-~,~ek ~ l~nod. HPMC, 
m l>~,~c-,-ed fo~m was ~ mm an o ~  dnnk taken at n~al 
lime. 
Res~/~- LOL cho~eslen~ e-~x,,-,ses (~ ± SD) ~ -3.4 ± 8.0% 
(placebo), -6.7 :~ 10.2% (2.5 9 q~ P > 0.05 vs. placebo). -13.2 ± 12.0% 
42.5 g bid. p < 0.001 vs. ~ ) ,  a~d -11.9 ± 109% 4375 9 bid, p < 0.001 
vs. ~ ) .  No ~/',,~,~-~.~s between ~ were obsen~d for HDL cho~es- 
tem~ and teglycende n~0,mms, or me modenco of gmm0~,:s~,~ and omer 
advsme experiences. 
Co~ctusk~s.- M closes of 25 g b~d and 3.75 g I~dL HIP,¢~C was ~=11 tcterated 
and ~ re¢luced LDL ct~oh~eroL Ihus may be a useful a(~onct to da~1 
fo~ the management of nald-to-moderade ptm~anj t ~ e ~ e ~  
~ T e n  Yearn of Simvasiat~ Tre=Imenl in F.mpedem:e 
M=rked ~ 
A.G. OP, son. J. M+mgaatd+ De~o~Me~mmme & Cam. Facu~ o~ ~'~,a/~ 
~okgreur=d: HMGCoA reductase ml~ibdor5 (statms) are increasingly used 
to lower elmrated low density lqX)l~rOl~n (LDL) cholesterol ~ Io presumer 
corenary Oisease. Long*erm safety a~l elftcacy ~ata (morn than 5 years) are 
scarce ~ non-emsting f~ tt~ stattns. 
Melt~ls: Simvestatin was ~ for 120 mon~ to 57 patients (36 males) 
~th immary I ~  ol wltom 30 were ~ to ha~e fam~tml 
hypercholesterelemia. Treatment was given first as per protocol and after 
two veam as compassionate use+ Treatment was monitored by the same 
physicians and research nurse through the ten years from 1986 to 1996 at 
n =,.~nthly in,'ewals at start, then even/six month. Mean pat~=nt age at start was 
53 (range 30-74) years. 
Resutts: After 10 years 17 patients had dropped out+ Slmvastatm dose 
ranged from 10 to 60 mg daily. Mean body we+gl~l increased by 3 kg. Mean 
baseline total and LDL cholesterol were 310 ± 81 (SO) and 245 :E 76 moj'dt, 
respe~vely. Total and LOL cholesterol decreased immediately on simvastatin 
and stayed constantly at this low level through ttte 10 years. At 120 months 
plasma total and LDL cholesterol was 32 and 38% lower than baseline. The 
percentage number of patients reaching tl~e LDL targets of 200, 123 and 96 
mg/dl at 120 months were 85, 20 and 3, respectively. Szmvestatin was well 
tolerated subjectively dudng the whole trial length. Increases in s-ALAT and 
s-ASAT activities were seen at seldom occasions and evenly spread over the 
period of treatment. No CK-elevaUon 10x the upper normal imit was seen. No 
cases of myopathy were noted. 
Conclusion: Ten years of simvaststin treatment in marked hypercholes- 
temlemia show that the drag is an effective hypochctestemlemic agent with 
few subjective or objective side effects. The drag seems well suited for long 
term preventive use against coronary disease. 
.m~Uem= ovcmmmteo~ t.0wem~'numw m~J 
~ntlom¢l=m S ~  on Com~ 
Oypmm om,  t (CABO) Oc=mmn = Y, al~ Af~' 
Surgery 
MG. Engelmano, A. Kne=, P, Cmm~, B, I .~ ,  O, $(m:~l+ 
" " , Mu~-'~, Gemw~ 
W~ h'w~t~gat~d th~ i ~  of Lova,~a~n an~ V~m~ E ~ 
t ,~  (~g~ ~ ~: O yearn, 11~ me~) who wxW~,mt C,~BO, PatW~ mcw~l  
L ~  (gfl~p t0 n =~ 3B) and ~ l m  plt~ V~n E (gRip 2, n =45) fo~ 
ve~x! t~ um~ ~ depe~ ~ me gene~ pmmm~ (m~up ~)+ 3+4 
graf~ (tOP internal mamma~ af1~y pMA| ~d ~OS veto g~)  m ~ 
b y ~  ~38,  ~amt  at 10e ± 8 we~ aae . ,~/ .  
~ :  Two yum a~ler m~lew, mere ~ a ~ m(Mmo, ot 
Cho~e,~,  t-DL.C an~ ~ n  B l~mm~en ~ 3 ~ (m ~ 
fo~ L~,<~: mdgctmn at mon~ 24), P!menls ol 9mups 1 and 2 ~ a e~fi~ 
ca~ ~ ~ ol gmtt o~du~on but mere vau ~o ~ 
~tlefe~= ~ 1o ~ cam treated pa~.  
I ( t .~)  10~ z 21 10~z5 ~.t== ;) tt30 (3%) 
II (LOva -,, V~ E) 10~ t 27 12R~7 t1B'~, | 1/31~ (3'%) 
In I~  ~)  I~  :~ ~ le/'~ |~l~'~ I 5/43 (1~)  
~005 ~0.05 ~005 
C.o~-~mon: These data ~ real Lovestatm alone was able to 
,~e  commm/graft petency 2 yearn after su~ge~. We fou~l no ~ 
etlecl ol Vmmm E ,*h~,~ adnmslm~ logemer w~h Lovamlm. 
~ - ~  Emlothe l la l  Dy=du~+'~lion I 
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IEmlotlltehi ~ ~ ~ With C l le~ Pakt: 
Pgot Flunm Cmta Fmm the NNLIBI Women's 
Imchemla S ~  Evaluation (WISE) 
FLA. Kmensky, L Lm, A. Boyeffe, JF. Lewm, S P ~ ,  BL  Sharat, 
C.N. BaJrey Met'z, C.J. Pepme. ~ o f ~  Game.s~/~ F/or/d~ 
USA 
~ .  to pmoo~namty male Sublects. system¢ and ~ ~ 
rml dysfurctmn am essocmted wdh CAD a~dtor CAD ,sk factora. This a~,x.~- 
abort has not been slu0ied m wOmellL 
Me~maS: In 29 womon wfftt chest pare. the mtabom~ between coronary 
( ~  by quamtat~ com~W ang+ugrap~ ~ [~I )  =~ 
brach~ ~eW ([BA| ~gh ~mkmo~ =~a:~xJ  bekYe and a~r ~e.~ma)  
eedornef~l lurctinn was mBmmed. 
~ .  Mean age was 56.1 440-7"3) ~.  H~sto~y ot hypam~,--~;-~ on- 
¢u~ed in 62%. tot~:oo use 55%, ~ i a  55%, fame/~ C./~ 45% InK! 
cflabetes I0%. Coronary endom~ dysfuncth0n (fa~ure to dilate with/Oh) 
was foond m 79% (23r29) w~e BA e~dom~ ~ (no fk~'H~edl- 
atod o~ia~on) occum~ in only 31% (~I~), A,T,,~-,Cj women ~ BA endothelial 
~ .  55% (.5/9) also Pad coronary endomel~ ~ .  However, 
in women w~ normal BA ~-~,thel~al functmn only 10% (2/20) had nom~l 
coronary eedothet~al fur~to~. Thus, a conoo~nt brach~l and ~- ,a ry  e~- 
doff~lial respo~,lse was seen in octy 24% (7F29). 
Conc/us/on: In women with chest pain and muttiPte CAD risk 1actom. corn" 
nan/endomel~ m frequent (79%). ~ not ~ l y  ~ted  
w=th systemK: endothel~ d ~ .  Hence. the a...,u.;octatton bet'~L'e~ sys- 
temic and coronary endothelial funo~o~ in women may be different han m 
men. 
~ C~ronk: Oral Supplement  of Vitamins.Improves 
Endothelial Function in Chronic SmoKers 
H. Etsut~. Y. Matsushima, M. Ayaon. H. Kusano. A. Hamabe. A. Uet~ta. 
B. Takase, A. Kurita, H. Nakamur'd. ~ Defense Mee~c~l Co#ege and 
Serf Defense Fome Central Hos~tal. Sa#ama nd Tokyo, Japan 
Endothelial function is known to be impaired m chro~c smokem po~t f  by 
o~o/gen-dem,'ed flee radicals. [T, etary supplement of antioxiOant vitamins may 
prOwde protec0on against endoth~i;~=! dysfunction. To investigate whether 
